ReviewNeurochemical research2026
Glutamatergic Neurotransmission Disruption as a Pathomechanism of Brain Damage in Disorders of Amino Acid and Organic Acid Metabolism: Insights from Animal and Cellular Studies.
Review in Neurochemical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Therapeutic Potential of Oxiracetam in Neurocognitive Disorders: A Narrative Review.Brain and behavior · 2026Review
- Agitation, Alzheimer's disease, and autophagy: mechanistic insights into aging pathways, gut microbiome, and artificial intelligence.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inborn errors of metabolism (IEMs) are inherited disorders biochemically characterized by the accumulation of potentially toxic metabolites in tissues and body fluids of the affected patients. Although clinical findings are heterogeneous, neurological symptoms, including coma and seizures associated with brain abnormalities, are very frequent. The mechanisms of neurotoxicity of the accumulated metabolites and their effects on cellular functions are still poorly established in many of these disorders. However, animal and cellular studies have shown that disturbances in glutamatergic neurotransmission, potentially leading to excitotoxicity, may represent a relevant mechanism of brain damage in some of these disorders. In agreement with this, treatments for some IEMs aim to mitigate overstimulation of N-methyl-D-aspartate (NMDA) receptors by NMDA receptor antagonists and to reduce the levels of the accumulated metabolites that activate these receptors. This review will focus on pre-clinical data showing disturbed glutamatergic neurotransmission in cells and animal models of IEMs that may offer perspectives for the development of novel adjuvant treatments for these diseases.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.